Clinical trials: Hematological Patients
Hematologic Malignancy, Treatment Adherence
Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment
The Improve study is a randomized controlled trial investigating the efficacy of adding comprehensive geriatric assessment and treatment to standard of care compared with standard of care in older, frail patients with…
- Conditions
- Hematologic Malignancy, Treatment Adherence, Treatment Complication, Frailty
- Trial name
- IMPROVE (NCT06373471)
- Testing
- Comprehensive geriatric assessment (CGA) and treatment
- Where
- Denmark
- Volunteers
- 152 people
- Sponsor
- Odense University Hospital
Hematologic Neoplasms, Neutropenia
The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants
The purpose of this observational study is to investigate whether a sufficient concentration of itraconazole can influence disappearance of a fever (defeverscence) when intravenous (into the vein) itraconazole is administered for…
- Conditions
- Hematologic Neoplasms, Neutropenia, Fever
- Trial name
- NCT01021683
- Testing
- Itraconazole
- Volunteers
- 203 people
- Sponsor
- Janssen Korea, Ltd., Korea
Immunogenicity, Hematological Malignancies
Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies. At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy for the prevention of Covid-19.
- Conditions
- Immunogenicity, Hematological Malignancies, Covid-19, Vaccine Response Impaired
- Trial name
- NCT04878822
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi
Leukemia, Myelodysplastic Syndrome
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
The purpose of this study is to find out whether the addition of blood stem cells from a close family member, when added to umbilical cord blood will make the transplant safer.
- Conditions
- Leukemia, Myelodysplastic Syndrome, Lymphoma
- Trial name
- NCT01682226
- Testing
- CliniMACS Fractionation system (Arm A), CliniMACS Fractionation system (Arm B), Haploidentical donor CD34+ cells
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignancy, Cancer
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
This is a prospective interventional study designed to investigate the effect of Immune Reconstitution clinic visits and pneumococcal vaccination (PCV-21) on infection risk, anti-infective prophylaxis adherence, and vaccine…
- Conditions
- Malignancy, Cancer, Hematological Malignancies, Lymphoma
- Trial name
- NCT07071909
- Testing
- Commercial CAR-T, Investigational CAR-T
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematological Malignancy
The Effect of Special Diets in Hematological Cancer Patients
Major weight loss and taste changes are well documented in patients with hematological cancer during chemotherapy. It has previously been documented, that such patients have preferences for much umami, a little sweet, sour and…
- Trial name
- NCT02880709
- Testing
- Special diet
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- Jens Rikardt Andersen
Pediatric Cancer, Solid Tumor Pediatric
Durvalumab and Tremelimumab for Pediatric Malignancies
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the…
- Conditions
- Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
- Trial name
- NCT03837899
- Testing
- Durvalumab / Tremelimumab Combination Therapy
- Where
- 19 sites in United States, France and 5 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Hematologic Neoplasms, Gram-Negative Bacterial Infections
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
This is a prospective, single-arm, observational, exploratory clinical study to evaluate whether the standard fixed dose of ceftazidime-avibactam (CAZ-AVI) achieves sufficient drug exposure (pharmacokinetic/pharmacodynamic, or…
- Conditions
- Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
- Trial name
- CZA-TDM (NCT07703644)
- Testing
- Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sizhou Feng
Advanced Solid Tumors, Hematological Malignancies
A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological…
- Trial name
- ATRIUM (NCT05338346)
- Testing
- ATG-018
- Where
- 5 sites in Australia
- Volunteers
- 22 people
- Sponsor
- Antengene Discovery Limited
Stem Cell Transplant Complications
Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies
Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT) are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at the moment of the graft.
- Trial name
- ZENITH (NCT03159845)
- Testing
- Zinc Sulfate Oral Product, Levofloxacin 500Mg Oral Tablet, Fluconazole 200mg tab
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Neutropenia, Thrombocytopenia
Effects of Levetiracetam Monotherapy on Various Hematological Parameters in Adult Patients Suffering of Epilepsy
Low therapeutic index of established antiepileptic drugs (AEDs) coupled with better understanding of the pathophysiology of seizure has encouraged the development of several novel AEDs.
- Conditions
- Neutropenia, Thrombocytopenia, Aplastic Anemia, Anemia
- Trial name
- NCT06491303
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Assiut University
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
SARS-CoV-2 Infection, Hematological Malignancies
COVID19-hematological Malignancies: the Italian Hematology Alliance
This is a retrospective/prospective, cohort, non-interventional observational study. This means that all patients with documented COVID and HM diagnosed between February 2020 and study initiation will compose the retrospective…
- Trial name
- NCT04352556
- Where
- 81 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi
Acute Leukemia, Acute Lymphoblastic Leukemia
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies).
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT04195633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML)
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
The purpose of the study was to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma…
- Conditions
- Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT04702425
- Testing
- VOB560, MIK665
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Malignancy, Non Hodgkin Lymphoma
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological…
- Conditions
- Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult
- Trial name
- NCT06206174
- Testing
- TGRX-814
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Hematologic Neoplasms
Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy
This study is aimed to determine the feasibility of obtaining and molecularly characterizing pre-treatment tumor biopsies, to determine the feasibility of obtaining and molecularly characterizing archival and post-treatment tumor…
- Trial name
- NCT01869218
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
GVHD - Graft-Versus-Host Disease, HSCT
Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg, in patients undergoing haploidentical…
- Conditions
- GVHD - Graft-Versus-Host Disease, HSCT, Haploidentical Stem Cell Transplantation
- Trial name
- REDUCy (NCT07193420)
- Testing
- Cyclophosphamide 35mg/kg/day, Cyclophosphamide 50mg/kg/day
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SIRS, Sepsis
Hematological Infection Score Compared to the Hospital Standard for Diagnosis of SIRS or Sepsis on ICU
CRP and PCT are not valid parameters of early infection in particularly postoperative patients. (Sanders et al., A\&A, June 2006, Vol.102; Katja et al., Shock, February 2001, Vol 15.2) Better detection systems for SIRS and sepsis…
- Trial name
- NCT01236703
- Where
- Germany
- Volunteers
- 207 people
- Sponsor
- Charite University, Berlin, Germany
Solid Tumor, Hematological Malignancy
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.
- Trial name
- NCT06106360
- Testing
- Locus Health iPhone App
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Inova Health Care Services